Seeking Alpha

More on Impax Laboratories (IPXL): Q3 misses on all fronts due to higher-than-anticipated...

More on Impax Laboratories (IPXL): Q3 misses on all fronts due to higher-than-anticipated acquisition costs, and litigation expenses associated with the voluntary withdrawal of one of its generic products from the market. Total revenue jumped 21% however, driven largely by better sales of Zomig, which was licensed from AstraZeneca (AZN). The Company also updated its FY12 financial outlook, now saying it expects total revenues for Q4 to decline by around 15% to 20% from Q3.

Check out Seeking Alpha’s new Earnings Center »

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs